Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27185443 | 0.84 | KMT2A (0.60) | CHRNA7PIM1LMNARECQLKMT2A | |
| SCHEMBL30950193 | 0.84 | LMNA (0.62) | CHRNA7LMNARECQLKMT2AMEN1 | |
| SCHEMBL4856085 | 0.84 | LMNA (0.62) | CHRNA7LMNARECQLKMT2AMEN1 | |
| SCHEMBL2010000 | 0.81 | MAOA (0.62) | LMNARECQLKMT2AMEN1NPC1 | |
| SCHEMBL930916 | 0.80 | CHRNA7 (0.45) | CHRNA7LMNARECQLKMT2AMEN1 | |
| SCHEMBL20604721 | 0.80 | LMNA (0.50) | CHRNA7LMNARECQLKMT2AMEN1 | |
| SCHEMBL17724009 | 0.80 | MAOA (0.51) | PIM1LMNARECQLKMT2AMEN1 | |
| SCHEMBL2896177 | 0.79 | CA12 (0.47) | PIM1LMNARECQLKMT2AMEN1 | |
| SCHEMBL6237938 | 0.79 | DAO (0.48) | CHRNA7PIM1LMNARECQLKMT2A | |
| SCHEMBL2432723 | 0.79 | MAOB (0.53) | PIM1LMNARECQLKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731608-A1 | ISOINDOLINONE-CONTAINING PARP INHIBITORS AND METHODS OF USE | Valo Health, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4370207-B1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| WO-2024261709-A1 | ISOINDOLINONE-CONTAINING PARP INHIBITORS AND METHODS OF USE | VALO HEALTH, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240368137-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12012398-B2 | Bicyclic compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4370207-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230391758-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-4213832-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1515967-B1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | FMR LLC | 2005-06-02 | — | — | US | disclosed |
| EP-1515967-A1 | 2-HETEROARYL CARBOXAMIDES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| EP-1461335-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003104227-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003055878-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | CHRNA2, CHRNA7, CHRNA3 | CHRNA7 2/4885PIM1 4868/4885LMNA 2429/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | CHRNA7 3528/4885PIM1 4538/4885LMNA 1698/4885 |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | GRIN2A, CNR2, GRIN2C | CHRNA7 70/4885PIM1 3148/4885LMNA 3055/4885 |
| US-20240368137-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CHRNA7 1145/4885PIM1 4845/4885LMNA 1049/4885 |
| US-12012398-B2 | Bicyclic compounds as androgen receptor modulators | AR, FSHR, NCOA3 | CHRNA7 925/4885PIM1 4834/4885LMNA 1186/4885 |
| US-20230391758-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | CHRNA7 3501/4885PIM1 3106/4885LMNA 1470/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | CHRNA7 4744/4885PIM1 4497/4885LMNA 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.